
Performance · Recovery · Longevity
Catalogue
Browse “Muscle/Performamnce, Recovery/Tissue, Weight Loss/Metabolic and Research Peptides“ and advanced wellness compounds. Prices are shown in South African Rand (ZAR).
Select a product to view available quantities, specifications and regulatory status. Quantities, documentation and pricing are confirmed before dispatch.
Tirzepatide 60mg (Peptide Aesthetix UPZEP 60)
|
Category: |
Weight Loss / Metabolic / Longevity |
|
SKU: |
TRW-TIRZ |
|
Price: |
R 3350.00 |
|
{{variant.name}}:
|
{{opt.name}}
{{opt.name}}
|
TEST RUN WELLNESS UPZEP 60 | Tirzepatide 60mg Multi-Dose Vial
UPZEP 60
(Tirzepatide 60mg) – Premium dual-agonist peptide for maximum weight loss and metabolic health. High-purity multi-dose vial with 2ml bacteriostatic water. Fast SA delivery from Test Run Wellness.
Product Overview
UPZEP 60 is a Tirzepatide 60mg multi-dose vial supplied with 2ml bacteriostatic water for reconstitution. Tirzepatide is a first-in-class unimolecular dual agonist that selectively binds to and activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors—the same targets as the native incretin hormones. The 60mg vial provides a high-concentration multi-dose format for extended research protocols.
How Tirzepatide Works: Dual GIP/GLP-1 Receptor Agonist Pathway
Tirzepatide is a 39-amino-acid modified peptide engineered for biased, balanced agonism at both incretin receptors. Structural studies reveal that conserved residues contribute similarly to binding at GLP-1R and GIPR, while C-terminal mutations weaken GLP-1R affinity and N-terminal mutations enhance GIPR affinity—producing a distinctive biased binding mode that underlies its pharmacological profile.
At the receptor level, tirzepatide enhances first- and second-phase insulin secretion and reduces glucagon levels, both in a glucose-dependent manner. The GIP component complements GLP-1 by improving fat metabolism and insulin sensitivity, while the GLP-1 component delays gastric emptying, suppresses appetite, and enhances satiety. Clinical evidence confirms that dual GIP/GLP-1 agonism produces superior glycaemic control and weight loss compared with selective GLP-1 receptor agonists, demonstrating synergistic interaction between the two incretin pathways.
Body Recomposition Benefits
Tirzepatide induces favourable body composition changes characterised by predominant fat loss with relative preservation of lean mass. In the SURMOUNT-1 body-composition substudy (n=160, DXA at baseline and Week 72), tirzepatide reduced body weight by −21.3%, fat mass by −33.9%, and lean mass by −10.9%; of the total body weight lost, approximately 75% was fat mass and 25% was lean mass. The ratio of total fat mass to total lean mass decreased from 0.93 at baseline to 0.70 at Week 72 with tirzepatide, compared with a change from 0.95 to 0.88 with placebo—indicating a meaningful shift toward a leaner body composition.
Pooled tirzepatide doses reduced fat mass by 15.9 kg (33.9%) and lean mass by 5.6 kg (10.9%) over 72 weeks in adults with obesity without diabetes. These findings support tirzepatide as a metabolically favourable agent for body recomposition, particularly when paired with resistance exercise and adequate protein intake to further protect skeletal muscle.
Titration Protocol
Tirzepatide is administered as a once-weekly subcutaneous injection. The recommended starting dose is 2.5 mg once weekly for 4 weeks, after which the dose is increased to 5 mg once weekly. The dose may then be increased in 2.5 mg increments after at least 4 weeks on the current dose, up to a maximum of 15 mg weekly for adults.
A standard escalation schedule is as follows:
· Weeks 1–4: 2.5 mg once weekly — starting dose for tolerance; not a maintenance dose
· Weeks 5–8: 5 mg once weekly — first escalation
· Weeks 9–12: 7.5 mg once weekly — second escalation
· Weeks 13–16: 10 mg once weekly — third escalation
· Weeks 17–20: 12.5 mg once weekly — fourth escalation
· Week 21+: 15 mg once weekly — maximum maintenance dose
The 2.5 mg dose is for treatment initiation and is not approved as a maintenance dosage. Dose escalation should only proceed if the current dose is well tolerated, to reduce the risk of gastrointestinal adverse reactions.
Combination Therapy
Combination strategies with tirzepatide are being actively investigated across multiple therapeutic areas. A prospective randomised controlled trial evaluated low-dose tirzepatide (5 mg once weekly) combined with metformin (1000 mg twice daily) versus metformin monotherapy in overweight/obese women with polycystic ovary syndrome (PCOS) over 16 weeks, with body weight as the primary outcome. This represents a targeted approach to metabolic and reproductive endpoints beyond general weight management.
In the body-composition space, a randomised, double-blind, placebo-controlled trial (NCT07671391) is evaluating LAE102 injection in combination with tirzepatide specifically for effects on body composition in participants with obesity. A separate Phase 2 study (ideNCT06373146) is investigating tirzepatide plus mibavademab compared with tirzepatide alone in adults with obesity, designed to determine whether the combination produces greater weight loss than tirzepatide monotherapy. Additional trials are exploring tirzepatide in combination with immunomodulatory agents (e.g., ixekizumab in psoriatic disease with overweight/obesity) and with investigational compounds such as BC-006 and eloralintide.
All combination approaches should be pursued under professional medical supervision.
Clinical Trial Record
Tirzepatide has demonstrated robust efficacy across the SURMOUNT clinical development programme and in head-to-head comparison with semaglutide:
· SURMOUNT-1 (body composition substudy): At Week 72, tirzepatide reduced body weight by −21.3%, fat mass by −33.9%, and lean mass by −10.9%, with approximately 75% of weight lost as fat mass.
· SURMOUNT-1 (3-year data): Mean body weight change was. −12.3% Tir with the 5 mg dose and −18.7% with the 10 mg dose. Three years of treatment in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes compared with placebo.
· SURMOUNT-5 (head-to-head vs semaglutide): In 751 adults with obesity but without type 2 diabetes, least-squares mean weight change at Week 72 was −20.2% with tirzepatide versus −13.7% with semaglutide (P<0.001). Waist circumference decreased by −18.4 cm with tirzepatide versus −13.0 cm with semaglutzepatide was superior for reductions in body weight and waist circumference.
· SURMOUNT-2 (T2D): Significant weight reduction and improvement in cardiometabolic risk parameters in participants with type 2 diabetes.
Regulatory Status
Tirzepatide is FDA-approved under the brand name Mounjaro for type 2 diabetes (approved 2022) and has since received an additional indication to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes at high cardiovascular risk. It is also FDA-approved as Zepbound for chronic weight management and for obstructive sleep apnea in adults with obesity. In April 2026, the FDA proposed a rule to permanently exclude tirzepatide (along with semaglutide and liraglutide) from the 503B bulks list, reflecting its status as a commercially available approved medicine rather than a compounding ingredient. UPZEP 60 is supplied by Test Run Wellness as a multi-dose research vial.
Technical Specifications
· Product Name: UPZEP 60
· Peptide: Tirzepatide
· Concentration: 60mg per vial
· Form: Multi-dose vial
· Reconstitution: Requires bacteriostatic water for reconstitution (2ml included)
· Administration: Once-weekly subcutaneous injection (per titration protocol)
· Supplier: Test Run Wellness (Wellness.testrun)
Important Medical Notice
Please consult your medical practitioner regarding your body requirements, as the dosing information provided contains guideline dosages. UPZEP 60 is intended for use under professional medical supervision. Tirzepatide is a prescription medication in many jurisdictions and should only be used under appropriate medical oversight. The most common adverse events in clinical trials were gastrointestinal (nausea, vomiting, diarrhoea, constipation), mostly mild to moderate in severity and occurring primarily during dose escalation. Tirzepatide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or MEN2. All dosing information is derived from published clinical data and approved product labelling.
Regulatory notice. Test Run Wellness is an independent supplier and is not the manufacturer of the products referenced. No product should be used without appropriate regulatory authorisation and professional medical oversight.